What is Alto Neuroscience's price / book?

Alto Neuroscience (ANRO) reported price / book of 3× in Q1 2026.

How has Alto Neuroscience's price / book changed year-over-year?

Alto Neuroscience's price / book increased by 601.9% year-over-year, from 0.4× to 3×.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Alto Neuroscience ANRO Price / book

Price / book at other companies

Xenon PharmaceuticalsXENE

4.1×+0.5×

Acadia PharmaceuticalsACAD

3×-0.6×

Rapport Therapeutics, Inc.RAPP

3.2×+1.9×

Praxis Precision Medicines, Inc.PRAX

6.4×+4.6×

MeiraGTx Holdings plcMGTX

174.8×+171×

LBR

LB Pharmaceuticals Inc Common StockLBRX

1.9×—

Other financials

Income statement

See full

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Balance sheet

See full

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Cash flow

See full

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Valuation

See full

Market cap$874.19M+1,335%

Enterprise value$630.81M-940%

Returns & leverage

See full

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Where this comes from

Calculated from Alto Neuroscience’s reported figures.

market cap/total stockholders equity=3×

Based on the most recent quarter.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alto Neuroscience's price / book?: Alto Neuroscience (ANRO) reported price / book of 3× in Q1 2026.
How has Alto Neuroscience's price / book changed year-over-year?: Alto Neuroscience's price / book increased by 601.9% year-over-year, from 0.4× to 3×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.